Anne Ruef
Overview
Explore the profile of Anne Ruef including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schroder R, Faiola E, Fernanda Urquijo M, Bey K, Meyhofer I, Steffens M, et al.
Schizophr Bull Open
. 2024 Aug;
3(1):sgac034.
PMID: 39144773
Schizotypy refers to a set of personality traits that bear resemblance, at subclinical level, to psychosis. Despite evidence of similarity at multiple levels of analysis, direct comparisons of schizotypy and...
2.
Koutsouleris N, Buciuman M, Vetter C, Weyer C, Zhutovsky P, Perdomo S, et al.
Res Sq
. 2024 Apr;
PMID: 38559014
Symptom heterogeneity characterizes psychotic disorders and hinders the delineation of underlying biomarkers. Here, we identify symptom-based subtypes of recent-onset psychosis (ROP) patients from the multi-center PRONIA (Personalized Prognostic Tools for...
3.
Hoheisel L, Kambeitz-Ilankovic L, Wenzel J, Haas S, Antonucci L, Ruef A, et al.
Biol Psychiatry Cogn Neurosci Neuroimaging
. 2024 Mar;
9(8):765-776.
PMID: 38461964
Background: Patients with psychosis and patients with depression exhibit widespread neurobiological abnormalities. The analysis of dynamic functional connectivity (dFC) allows for the detection of changes in complex brain activity patterns,...
4.
Wenzel J, Badde L, Haas S, Bonivento C, Van Rheenen T, Antonucci L, et al.
Neuropsychopharmacology
. 2023 Sep;
49(3):573-583.
PMID: 37737273
Cognitively impaired and spared patient subgroups were identified in psychosis and depression, and in clinical high-risk for psychosis (CHR). Studies suggest differences in underlying brain structural and functional characteristics. It...
5.
Walter N, Wenzel J, Haas S, Squarcina L, Bonivento C, Ruef A, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2023 Sep;
128:110864.
PMID: 37717645
Clinical and neuroimaging data has been increasingly used in recent years to disentangle heterogeneity of treatment response to cognitive training (CT) and predict which individuals may achieve the highest benefits....
6.
Buciuman M, Oeztuerk O, Popovic D, Enrico P, Ruef A, Bieler N, et al.
Biol Psychiatry Cogn Neurosci Neuroimaging
. 2023 Jun;
8(12):1207-1217.
PMID: 37343661
Background: Formal thought disorder (FThD) is a core feature of psychosis, and its severity and long-term persistence relates to poor clinical outcomes. However, advances in developing early recognition and management...
7.
Korda A, Andreou C, Rogg H, Avram M, Ruef A, Davatzikos C, et al.
Transl Psychiatry
. 2022 Nov;
12(1):481.
PMID: 36385133
Structural MRI studies in first-episode psychosis and the clinical high-risk state have consistently shown volumetric abnormalities. Aim of the present study was to introduce radiomics texture features in identification of...
8.
Schwarzer J, Meyhoefer I, Antonucci L, Kambeitz-Ilankovic L, Surmann M, Bienek O, et al.
Neuropsychopharmacology
. 2022 Aug;
47(12):2051-2060.
PMID: 35982238
Subtle subjective visual dysfunctions (VisDys) are reported by about 50% of patients with schizophrenia and are suggested to predict psychosis states. Deeper insight into VisDys, particularly in early psychosis states,...
9.
Dwyer D, Buciuman M, Ruef A, Kambeitz J, Dong M, Stinson C, et al.
JAMA Psychiatry
. 2022 May;
79(7):677-689.
PMID: 35583903
Importance: Approaches are needed to stratify individuals in early psychosis stages beyond positive symptom severity to investigate specificity related to affective and normative variation and to validate solutions with premorbid,...
10.
Penzel N, Sanfelici R, Antonucci L, Betz L, Dwyer D, Ruef A, et al.
Schizophrenia (Heidelb)
. 2022 Mar;
8(1):19.
PMID: 35264631
Continued cannabis use (CCu) is an important predictor for poor long-term outcomes in psychosis and clinically high-risk patients, but no generalizable model has hitherto been tested for its ability to...